**
In a desperate race against time, health officials in the Democratic Republic of the Congo (DRC) have initiated groundbreaking drug trials to combat a raging Ebola outbreak. With confirmed cases soaring and the death toll climbing, the first patients were enrolled just six weeks after the World Health Organization (WHO) declared the situation a public health emergency on 17 May. The stakes are high, and the local population is anxiously awaiting a breakthrough.
A Community on Edge
As the Bundibugyo strain of Ebola spreads through the Ituri region, the atmosphere is thick with anxiety and impatience. Neema Haba, a local banana seller and mother of three, expressed the community’s distress: “I hope these drug trials proceed quickly. Financially, we are being driven to the brink by this outbreak, and nothing is going right. We are struggling to provide for our children.”
The figures are grim: as of 9 July, there have been 1,792 confirmed cases and 625 deaths, with the WHO describing the outbreak as still “in the expansion phase.” The response relies heavily on traditional methods—identifying and isolating cases, as well as tracking contacts—but trust in health authorities is low, making these efforts increasingly difficult.
Frontline Workers Face Hostility and Hardship
The challenges are compounded for frontline workers who are risking their lives in an already perilous situation. Ovide Maliabo, a driver for a burial team in Rwampara, highlighted the dangers of their work amidst community mistrust. “At one point, we narrowly escaped being lynched,” he recounted. “It’s a shame that we aren’t being financially supported.”
Bahati John, leading the burial team, described the physical and emotional toll of their efforts, revealing that he lost a tooth in an attack by locals. “Since we started working on 15 May, we haven’t seen a single penny. We are the breadwinners of our families, and our families are suffering.” The situation is exacerbated by shortages of essential protective equipment and transport, further hindering the response.
The Race for Effective Treatments
With no approved drugs currently available, hopes now rest on the Partners treatment trial, which is testing two potential therapies: remdesivir and MBP134. Remdesivir, an antiviral developed by Gilead Sciences, and MBP134, a monoclonal antibody created by Mapp Biopharmaceutical, are both administered intravenously. These treatments have shown promise in animal models, but researchers are keen to understand their efficacy in humans.
Prof. Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp underscored the urgency of the trials, stating, “We need to test it in humans. Basically, what we want to see is if they can indeed lower mortality.” While Bundibugyo typically has a lower death rate than the more lethal Zaire strain, it still claims approximately one-third of those infected.
The trial aims to enrol between 700 and 1,000 patients, with sufficient supplies of both drugs secured for 1,200 participants. WHO officials are ensuring that resources remain available should the treatments prove effective. Notably, the trial is inclusive, allowing participants of all ages, including pregnant and breastfeeding women, who are often excluded from medical research.
Swift Action and International Support
Prof. Amanda Rojek, an international principal investigator for the trial, praised the rapid response in DRC compared to earlier outbreaks. “If we look back at West Africa, where it took over a year to start clinical trials, we’re very proud of the team that we’ve managed to achieve this in just six weeks.” This swift action is crucial; the sooner effective treatments are available, the better the chances of turning the tide against the outbreak.
The DRC’s National Biomedical Research Institute has played a pivotal role in this rapid response, and further trials are set to begin soon, including one exploring whether a drug called obeldesivir can prevent illness in those exposed to the virus.
Why it Matters
The situation in the DRC highlights a critical intersection of public health, community trust, and scientific progress. The rapid establishment of treatment trials not only offers a glimmer of hope in the face of a deadly outbreak but also underscores the importance of effective communication and support for frontline workers. As the world watches, the outcome of these trials could reshape the fight against Ebola, offering insights that extend far beyond the DRC, potentially influencing responses to future outbreaks globally.